HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis,

Slides:



Advertisements
Similar presentations
Brent Hoffman. HOXA9 is one of the HOX transcription factors regulating Anterior to Posterior patterning in early development.
Advertisements

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.
Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo by Ilze Bot, Jian Guo, Miranda Van Eck,
Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene by Christof Dame, Karin M. Kirschner, Katharina V. Bartz, Thomas.
Formation of human hepatocytes by human hematopoietic stem cells in sheep by Graça Almeida-Porada, Christopher D. Porada, Jason Chamberlain, Ali Torabi,
Phenotypic and Functional Changes Induced at the Clonal Level in Hematopoietic Stem Cells After 5-Fluorouracil Treatment by Troy D. Randall, and Irving.
STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia by Maurizio Mangolini, Jasper de Boer, Vanessa Walf-Vorderwülbecke,
Do HSCs divide asymmetrically?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
TCR-MHC-peptide(s): in vivo veritas
“Vitamin hypothesis”: explanation for allergy increase?
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo by Farideh Miraki-Moud, Essam.
by Muhammed A. Mir, Mrinal M. Patnaik, and Joerg Herrmann
Next-generation leukemia immunotherapy
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
Gupta V, Tallman MS, Weisdorf DJ
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia by Shuchi Agrawal, Wolf-Karsten Hofmann, Nicola Tidow, Mathias Ehrich,
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Rituximab-induced tumor cell agglutination
Tax fingerprint in adult T-cell leukemia
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,
Mechanisms of HIV-associated lymphocyte apoptosis
by Christopher J. Ott, Nadja Kopp, Liat Bird, Ronald M
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
Acute promyelocytic leukemia, microgranular variant
by Keren Mizrahi, and Nadir Askenasy
Taking a leaf from the book of oral tolerance
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Human NK cells can control CMV infection in the absence of T cells
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia by Sayed Shahabuddin Hoseini, Hongfen Guo, Zhihao Wu, Miho.
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Volume 20, Issue 1, Pages (July 2011)
Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors by Yu-Ting Chang, Daniela Hernandez,
Decreased expression of cell cycle– and apoptosis-related genes in Aml1-excised leukemia cell. Decreased expression of cell cycle– and apoptosis-related.
HoxA9 directly regulates cell cycle control genes.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Sickle cells and sickle trait in thrombosis
Schematic model of the mechanism of Tak1 protection of HSPC survival.
Volume 14, Issue 8, Pages (March 2016)
Mary Eapen  Biology of Blood and Marrow Transplantation 
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
HoxA9 is degraded by neutrophil granule proteases.
Patient Tregs express normal levels of suppression.
by Jan J. Cornelissen, and Didier Blaise
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Presentation transcript:

HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis, Marry van den Heuvel-Eibrink, Christian M. Zwaan, Andrew L. Kung, and Scott A. Armstrong Blood Volume 113(11): March 12, 2009 ©2009 by American Society of Hematology

ShRNA-mediated knockdown of HOXA9 expression in human t(9;11) MOLM-14 and t(4;11) SEMK2 cells and murine leukemia stem cells (L-GMP). Joerg Faber et al. Blood 2009;113: ©2009 by American Society of Hematology

Analysis of phenotypic consequences after shRNA-mediated HOXA9 suppression in t(9;11) MOLM-14 AML and t(4;11) SEMK2 ALL cells. Joerg Faber et al. Blood 2009;113: ©2009 by American Society of Hematology

Effects of HOXA9 suppression in human t(9;11) MOLM-14 and t(4;11) SEMK2 cells. Joerg Faber et al. Blood 2009;113: ©2009 by American Society of Hematology

Induction of apoptosis by HOXA9 suppression is significantly correlated with the presence of the MLL-fusion oncogene. Joerg Faber et al. Blood 2009;113: ©2009 by American Society of Hematology

HOXA9 suppression induces apoptosis in primary MLL-rearranged human AML cells. Joerg Faber et al. Blood 2009;113: ©2009 by American Society of Hematology

Assessment of the effects of HOXA9 suppression in vivo using bioluminescent imaging. Joerg Faber et al. Blood 2009;113: ©2009 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.